Predictions
Bio-Gate AG
Start price
Target price
Perf. (%)
€3.70
02.05.21
02.05.21
-
02.05.22
02.05.22
1.08%
16.05.21
16.05.21
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
CytoTools AG
Start price
Target price
Perf. (%)
€10.20
12.08.20
12.08.20
€26.00
04.11.21
04.11.21
56.86%
13.04.21
13.04.21
Could be very worthwhile Investment >20% year
Differentiated customer and product portfolio
Vivoryon Therapeutics N.V.
Start price
Target price
Perf. (%)
€14.52
04.02.21
04.02.21
€35.00
10.88%
21.03.21
21.03.21
Bio-Gate AG
Start price
Target price
Perf. (%)
€4.22
21.02.21
21.02.21
-
21.02.22
21.02.22
-5.21%
06.03.21
06.03.21
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Bio-Gate AG
Start price
Target price
Perf. (%)
€4.36
13.12.20
13.12.20
-
13.12.21
13.12.21
-5.96%
10.01.21
10.01.21
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Vivoryon Therapeutics N.V.
Start price
Target price
Perf. (%)
€4.00
06.04.20
06.04.20
-
04.11.21
04.11.21
132.50%
10.12.20
10.12.20
Elanix Biotechnologies AG
Start price
Target price
Perf. (%)
€0.30
06.04.20
06.04.20
-
04.11.21
04.11.21
110.00%
10.12.20
10.12.20
Bio-Gate AG
Start price
Target price
Perf. (%)
€4.10
14.11.20
14.11.20
-
14.11.21
14.11.21
-11.71%
30.11.20
30.11.20
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Nanorepro AG
Start price
Target price
Perf. (%)
€3.36
16.11.20
16.11.20
-
16.11.21
16.11.21
0.60%
26.11.20
26.11.20
Could be worthwhile Investment >10% per year
Standard Investments for future growth
Revenue growth >5% per year expected
Lower EBIT Margin than peer group
Nanorepro AG
Start price
Target price
Perf. (%)
€2.94
11.11.20
11.11.20
-
11.11.21
11.11.21
14.29%
16.11.20
16.11.20
Could be worthwhile Investment >10% per year
Standard Investments for future growth
Revenue growth >5% per year expected
Lower EBIT Margin than peer group
aap Implantate AG
Start price
Target price
Perf. (%)
€9.26
01.03.19
01.03.19
€15.00
04.11.21
04.11.21
-94.30%
08.11.20
08.11.20